conclusions of Palatin Technologies...

conclusions of Palatin Technologies Inc.'s (Cranbury, NJ) Phase 2a clinical trial of PT-141 a treatment for sexual dysfunction, showed that the research drug had a positive issue on its primary and secondary endpoints--duration of base rigidity greater than 60% of abounding base rigidity versus placebo, and of base rigidity greater than 80% of replete base rigidity versus placebo. Twenty-four bring under rules with mild-to-moderate male erectile dysfunction, who were responsive to generally available oral treatments, were enlisted in this trial. Each received the placebo and pair doses of the study